Article
Immunology
Saad I. Mallah, Abdulla Alawadhi, Jaleela Jawad, Pearl Wasif, Basma Alsaffar, Ejlal Alalawi, Afaf Merza Mohamed, Alexandra E. Butler, Batool Alalawi, Donia Qayed, Sayed Ali Almahari, Ali Mubarak, Aalaa Mubarak, Sawsan Saeed, Ahmed Humaidan, Nitya Kumar, Stephen Atkin, Manaf Alqahtani
Summary: A study found that heterologous prime-boost vaccination with BNT162b2 and BBIBP-CorV vaccines can enhance the immune response to SARS-CoV-2 in individuals who have received two doses of a vaccine. This approach appears to be safe and well tolerated.
Article
Immunology
Saraiorn Thonginnetra, Kriangkrai Tawinprai, Krongkwan Niemsorn, Pathariya Promsena, Manunya Tandhansakul, Naruporn Kasemlawan, Natthanan Ruangkijpaisal, Narin Banomyong, Nanthida Phattraprayoon, Pisuttikan Rangkakulnuwat, Preeda Vanichsetakul, Teerapat Ungtrakul, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Nithi Mahanonda
Summary: Coronavirus disease 2019 has negatively impacted child health and learning. This study on the safety of the BBIBP-CorV vaccine shows that adolescents receiving two doses may experience mild to moderate side effects, but overall the vaccine is safe.
Article
Microbiology
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, Fatemeh Ashrafian, Mona Sadat Larijani, Vicente Verez-Bencomo, Maria Eugenia Toledo-Romani, Carmen Valenzuela Silva, Mostafa Salehi-Vaziri, Sarah Dahmardeh, Delaram Doroud, Mohammad Banifazl, Ehsan Mostafavi, Anahita Bavand, Amitis Ramezani
Summary: This study evaluated and compared the efficacy of PastoCovac Plus protein-subunit vaccine with ChAdOx1-S and BBIBP-CorV in volunteers who had been primed with two doses of ChAdOx1-S or BBIBP-CorV vaccines. The results showed that PastoCovac Plus effectively increased specific antibody levels and could be used in heterologous regimens to boost humoral immune responses.
Article
Multidisciplinary Sciences
Natalia Vargas-Herrera, Manuel Fernandez-Navarro, Nestor E. Cabezudo, Percy Soto-Becerra, Gilmer Solis-Sanchez, Stefan Escobar-Agreda, Javier Silva-Valencia, Luis Pampa-Espinoza, Ricardo Bado-Perez, Lely Solari, Roger V. Araujo-Castillo
Summary: This study evaluated the reactogenicity and immunogenicity of COVID-19 booster doses in healthcare workers and elderly patients in Lima, Peru. The results showed that both vaccine regimens were safe, well-tolerated, and highly immunogenic.
Article
Immunology
Vladimir Petrovic, Vladimir Vukovic, Aleksandra Patic, Milos Markovic, Mioljub Ristic
Summary: A study evaluated the medium-term kinetics of anti-SARS-CoV-2 antibodies after vaccination with BNT162b2, BBIBP-CorV, and Gam-COVID-Vac. The results showed a decline in antibody levels at six months, suggesting the need for additional booster doses.
Article
Immunology
Khaled Greish, Abdulla Alawadhi, Ahmed Jaradat, Amer Almarabheh, Marwa AlMadhi, Jaleela Jawad, Basma Alsaffar, Ejlal Alalawi, Adel Alsayyad, Afaf Merza, Batool Alalawi, Donia Qayed, Ahmed Humaidan, Manaf Al Qahtani
Summary: This study evaluated the reactogenicity and immunogenicity of the BBIBP-CorV vaccine in children aged 3 to 12. The results showed that the vaccine is safe and well-tolerated in this age group, and can induce an effective immune response and the production of neutralizing antibodies.
Article
Multidisciplinary Sciences
Nawal Al Kaabi, Abderrahim Oulhaj, Subhashini Ganesan, Farida Ismail Al Hosani, Omer Najim, Halah Ibrahim, Juan Acuna, Ahmed R. Alsuwaidi, Ashraf M. Kamour, Ashraf Alzaabi, Badreyya Ahmed Al Shehhi, Habiba Al Safar, Salah Eldin Hussein, Jehad Saleh Abdalla, Dalal Saeed Naser Al Mansoori, Ahmed Abdul Kareem Al Hammadi, Mohammed A. Amari, Ahmed Khamis Al Romaithi, Stefan Weber, Santosh Elavalli, Islam Eltantawy, Noura Khamis Alghaithi, Jumana Nafiz Al Azazi, Stephen Geoffrey Holt, Mohamed Mostafa, Rabih Halwani, Hanif Khalak, Wael Elamin, Rami Beiram, Walid Zaher
Summary: The BBIBP-CorV (Sinopharm) vaccine has been assessed for its effectiveness against severe COVID-19 disease using data from Abu Dhabi. The vaccine showed an effectiveness of 80% against hospitalization, 86% against critical care admission, and 84% against death. However, the effectiveness declined over time, suggesting the need for booster doses to increase protection against severe COVID-19 outcomes.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Georg M. N. Behrens, Joana Barros-Martins, Anne Cossmann, Gema Morillas Ramos, Metodi Stankov, Ivan Odak, Alexandra Dopfer-Jablonka, Laura Hetzel, Miriam Koehler, Gwendolyn Patzer, Christoph Binz, Christiane Ritter, Michaela Friedrichsen, Christian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Verena Kraehling, Guenter Bernhardt, Markus Hoffmann, Stefan Poehlmann, Thomas Krey, Berislav Bosnjak, Swantje Hammerschmidt, Reinhold Foerster
Summary: Heterologous prime/boost vaccination with a vector-based approach followed by an mRNA vaccine has been found to induce better protective immunity compared to homologous vaccination. A third vaccine dose enhances the waning anti-spike IgG and restores neutralizing antibody responses against several variants of the virus, except for the Omicron variant.
NATURE COMMUNICATIONS
(2022)
Article
Clinical Neurology
Miguel A. Vences, Mary M. Araujo-Chumacero, Edu Cardenas, Diego Canales, Arturo Alvarez, Ebelin Barja, Maria Fe Albujar, Diego Urrunaga-Pastor
Summary: This report is the first case in Latin America of severe encephalitis associated with BBIBP-CorV (Sinopharm) vaccination. The patient had atypical imaging patterns, early clinical relapse, and a favorable response to corticosteroid therapy.
Article
Immunology
Xuesong Xu, Yi Hong, Erjing Chen, Yaping Wang, Biao Ma, Jiali Li, Wei Su, Yuxin Zhou, Mingzhou Zhang
Summary: This study discusses the inhibitory abilities of antibodies induced by primary and booster vaccines against different strains of SARS-CoV-2. The results show that homologous inactivated vaccines have the strongest inhibitory effects on the wild-type strain, but exhibit resistance against B.1.351, B.1.617.2, and B.1.1.529 mutants. Heterologous booster vaccination can significantly restore humoral immune responses and generate stronger antibody responses against various mutant strains.
Article
Immunology
Yunhua Wei, Yan Wang, Jian Liu, Yan Zha, Yuqi Yang, Ni Li, Yalin Zhou, Jinli Zhu, Neil Roberts, Lin Liu, Yaying Li
Summary: A comparative analysis was conducted to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines. The study found that doctors and women had a higher risk of adverse reactions, but overall, the rates of AEFI in all three booster groups were acceptable.
Article
Hematology
Rezvan Hosseinzadeh, Mohammad Barary, Hamed Mehdinezhad, Terence T. Sio, Florian Langer, Sahar Khosravi
Summary: This study reports a suspected case of VITT after vaccination with an inactivated vaccine. The patient developed severe thrombocytopenia and thrombosis symptoms after vaccination, and was diagnosed and treated through laboratory analysis and ultrasound examination.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Immunology
Hanisah Sharif, Hazim Ghani, Liyana Ahmad, Saifuddien Bagol, Justin Wong, Chee Wah Tan, Feng Zhu, Lin-Fa Wang, Lin Naing, Anne C. Cunningham
Summary: The study found that both homologous and heterologous booster doses can significantly increase neutralising antibody levels in individuals vaccinated with BBIBP-CorV. Additionally, there are differences in the duration of neutralising antibodies for mRNA vaccines, with mRNA-1273 showing longer persistence.
Article
Public, Environmental & Occupational Health
Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Chen Su, Tianfang Xu, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal, Yuntao Zhang, Xiaoming Yang
Summary: This retrospective cohort study in Morocco found that Sinopharm's BBIBP-CorV vaccine is highly effective in preventing serious or critical hospitalization for COVID-19, particularly among working-age adults.
Article
Biochemistry & Molecular Biology
Nawal Al Kaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Mengjie Yang, Islam Eltantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
Summary: This study demonstrates that heterologous booster vaccination with NVSI-06-07 enhances immunity against SARS-CoV-2 and provides superior protection compared to homologous boosters. NVSI-06-07 shows good safety and immunogenicity as a heterologous booster in individuals previously vaccinated with BBIBP-CorV.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Infectious Diseases
Rima Moghnieh, Hani Tamim, Amin Abyad, Marwa Jadayel, Lyn Awad, Dania Abdallah, Nicholas Haddad, Jessica Berberi, Rawya Alwazir, Rida Taher, Tamima Jisr, Rawad Lakkis, Kamal Zahran, Ahmad Ibrahim
Article
Oncology
Rima Moghnieh, Lyn Awad, Dania Abdallah, Marwa Jadayel, Loubna Sinno, Hani Tamim, Tamima Jisr, Salam El-Hassan, Rawad Lakkis, Rima Dabbagh, Abdul Rahman Bizri
JOURNAL OF CHEMOTHERAPY
(2020)
Article
Public, Environmental & Occupational Health
Rima Moghnieh, Hani Tamim, Marwa Jadayel, Dania Abdallah, Rasha Al-Kassem, Hind Kadiri, Hani Hafez, Salam Al-Hassan, Lina Ajjour, Rawad Lakkis, Tamima Jisr, Nadia-Lara Samaha, Nicholas Haddad
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2020)
Article
Public, Environmental & Occupational Health
Rima Moghnieh, Dania Abdallah, Abdul Rahman Bizri
Summary: Between December 31, 2019, and August 30, 2020, the COVID-19 pandemic has caused more than 25 million cases and 843,158 deaths worldwide. With the threat of future waves, countries are preparing contingency plans to mitigate the impact. The time frame for achieving herd immunity and the uncertainty of vaccine availability necessitate proactive measures and preparedness plans.
DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
(2022)
Article
Multidisciplinary Sciences
Rima Moghnieh, Dania Abdallah, Marwa Jadayel, Wael Zorkot, Hassan El Masri, Marie Joe Dib, Tasnim Omar, Loubna Sinno, Rawad Lakkis, Tamima Jisr
Summary: This study investigated the incidence and risk factors of Carbapenem-resistant Enterobacterales (CRE) acquisition in inpatients with 3rd generation cephalosporin-resistant (3GCR) Enterobacterales at a tertiary-care hospital in Lebanon, and proposed a risk prediction score. The analysis identified several independent risk factors for CRE acquisition including history of cerebrovascular disease, hematopoietic cells transplantation, presence of chronic wound, recent endoscopy, nosocomial site of acquisition, and prior use of meropenem. A risk score ranging from 0 to 25 was developed based on these factors and demonstrated predictive value in identifying patients likely to acquire CRE.
SCIENTIFIC REPORTS
(2021)
Article
Infectious Diseases
Rima A. Moghnieh, Jihane A. Moussa, Mohamed Abdel Aziz, Ghassan M. Matar
Summary: This study summarized the antimicrobial resistance of Gram-negative bacteria to various antimicrobial agents in Lebanon, Jordan, and Iraq, indicating an escalating trend in antimicrobial resistance issues.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Oncology
Rima Moghnieh, Ahmad Khalil, Nazih Bizri, Nadine Francis, Sabine Imad, Maria Mezher, Zahraa Mrad, Jad Ibrahim, Kamal Zahran, Farah Farroukh, Malak Itani, Amani Assaad, Loubna Sinno, Dania Abdallah, Ahmad Ibrahim
Summary: This study aimed to determine the prevalence and contributing factors to QTc prolongation in hematopoietic cell transplantation (HCT) recipients who received fluoroquinolones and triazoles for chemoprophylaxis. The results showed that 22% of the recipients developed QTc prolongation, with female gender being a contributing factor. There were also trends observed in patients with thyroid disease, vomiting and diarrhea, baseline electrolyte imbalances, and patients receiving multiple drugs with a risk of QTc prolongation. However, none of the patients with QTc prolongation experienced serious arrhythmias or death.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Review
Infectious Diseases
Nesrine A. Rizk, Rima Moghnieh, Nisrine Haddad, Marie-Claire Rebeiz, Rony M. Zeenny, Joya-Rita Hindy, Gabriella Orlando, Souha S. Kanj
Summary: This paper aims to evaluate the potential impact of COVID-19 on global antimicrobial resistance and antimicrobial stewardship, with a focus on countries in the Arab league. The authors highlight potential issues such as antibiotic overuse and resistance exacerbation during the pandemic.
Letter
Immunology
Rima Moghnieh, Dania Abdallah, Mohamed H. Sayegh, Abdul Rahman Bizri
Article
Immunology
Rima Moghnieh, Claude El Hajj, Dania Abdallah, Nayla Jbeily, Abdul Rahman Bizri, Mohamed H. Sayegh
Summary: This study examined the humoral immunity levels and effectiveness of two COVID-19 vaccines in a cohort of employees of the National Airline company in Lebanon. It also investigated the impact of booster vaccinations and hybrid immunity. The findings showed that the BNT162b2 vaccine had higher effectiveness against the Delta variant compared to the Gam-COVID-Vac vaccine. However, the protection and antibody levels against the Omicron variant were severely compromised. The study also found that a homologous booster after a primary vaccination induced a higher immune response compared to a heterologous booster. Hybrid immunity provided better protection against Delta and Omicron infections compared to vaccination-induced immunity in COVID-19-naive individuals.
Review
Immunology
Abdulrahman Bizri, Ahmad Ibrahim, Elissar Dagher, Madonna Matar, Malek Mohammed, Nizar Bitar, Paola Atallah, Rima Moghnieh, Umayya Musharrafieh, Zeina Aoun-Bacha
Summary: Pneumococcal disease burden is high among adults in Lebanon, but there are no recommendations for adult vaccination. Experts suggest increasing adult vaccination rate and raising awareness.
Article
Public, Environmental & Occupational Health
Rola Husni, Maroun Bou Zerdan, Nadia Samaha, Mariana Helou, Youssef Mahfouz, Rim Saniour, Sawsan Hourani, Harout Kolanjian, Claude Afif, Eid Azar, Tamima El Jisr, Jacques Mokhbat, Emma Abboud, Rita Feghali, Edmond Abboud, Hiam Matta, Gilbert Karayakouboglo, Madonna Matar, Rima Moghnieh, Ziad Daoud
Summary: This study describes the epidemiology of non-albicans Candida (NAC) infections and their resistance in Lebanese hospitals. The most common NAC species isolated were Candida glabrata (40.8%) and Candida tropicalis (23.1%). The study also found differing susceptibility to antifungal treatments among these species. Proper identification of these organisms is crucial for effective treatment.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Endocrinology & Metabolism
Julio A. Chirinos, Patricio Lopez-Jaramillo, Evangelos J. Giamarellos-Bourboulis, Gonzalo H. Davila-del-Carpio, Abdul Rahman Bizri, Jaime F. Andrade-Villanueva, Oday Salman, Carlos Cure-Cure, Nelson R. Rosado-Santander, Mario P. Cornejo Giraldo, Luz A. Gonzalez-Hernandez, Rima Moghnieh, Rapti Angeliki, Maria E. Cruz Saldarriaga, Marcos Pariona, Carola Medina, Ioannis Dimitroulis, Charalambos Vlachopoulos, Corina Gutierrez, Juan E. Rodriguez-Mori, Edgar Gomez-Laiton, Rosa Cotrina Pereyra, Jorge Luis Ravelo Hernandez, Hugo Arbanil, Jose Accini-Mendoza, Maritza Perez-Mayorga, Charalampos Milionis, Garyfallia Poulakou, Gregorio Sanchez, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo J. Ayala-Garcia, Carlos A. Castro-Callirgos, Rosa M. Alfaro Carrasco, Willy Garrido Lecca Danos, Tiffany Sharkoski, Katherine Greene, Bianca Pourmussa, Candy Greczylo, Juan Ortega-Legaspi, Douglas Jacoby, Jesse Chittams, Paraskevi Katsaounou, Zoi Alexiou, Styliani Sympardi, Nancy K. Sweitzer, Mary Putt, Jordana B. Cohen
Summary: Fenofibrate has no significant effect on clinically relevant outcomes in patients with COVID-19.
